Aclaris Therapeutics, Inc., a Malvern, Pennsylvania-based specialty pharmaceutical company, closed on a $21m Series B financing.
Backers included existing investors Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures.
Founded in August of 2012 and led by Dr. Neal Walker, president and CEO, Aclaris Therapeutics develops a topically applied therapy directed toward the removal of seborrheic keratosis (SK) and other verrucoid lesions of the skin. The funding follows recent positive results from a Phase 2 clinical trial of its lead product candidate, A-101, which demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK).
Two additional Phase 2b clinical trials evaluating A-101 in the treatment of SK are ongoing.
The company has raised more than $42m since its formation.
FinSMEs
02/10/2014